Loading...
XNAS
TPST
Market cap12mUSD
Oct 08, Last price  
0.77USD
1D
-2.70%
1Q
-20.86%
Jan 2017
-99.98%
IPO
-100.00%
Name

Tempest Therapeutics Inc

Chart & performance

D1W1MN
XNAS:TPST chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
165.92%
Rev. gr., 5y
1.18%
Revenues
0
0009,735,000277,000653,000295,00000000000
Net income
-26m
L-37.24%
-2,725,000-13,510,000-29,044,000-49,520,000-73,219,000-82,260,000-84,578,000-27,192,000-44,568,000-19,118,000-28,302,000-35,709,000-29,491,000-41,843,000-26,262,000
CFO
-27m
L-18.79%
-11,156,000-18,094,000-30,588,000-50,286,000-61,734,000-20,340,000-23,647,000-41,222,000-19,017,000-25,957,000-31,072,000-27,357,000-33,027,000-26,820,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Millendo Therapeutics, Inc. is an advanced biopharmaceutical firm dedicated to developing innovative therapies for rare hormonal disorders, primarily within the United States. The company's key therapeutic candidates include livoletide, an investigational drug aimed at Prader-Willi syndrome; nevanimibe, an experimental compound designed for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist intended to alleviate vasomotor symptoms (such as hot flashes) in women experiencing menopause. This enterprise maintains its primary operational base in Ann Arbor, Michigan.

Key people

Stephen Brady
President, Principal Executive Officer, Director · since 2025
Samuel Whiting
Executive Vice President, Chief Medical Officer · since 2020
Nicholas Maestas
Vice President - Strategy and Finance, Corporate Secretary · since 2022
Christine Pellizzari
Independent Director · since 2021
Michael Raab
Independent Director · since 2026
Ronit Simantov
Independent Director · since 2021
URL
https://www.tempesttx.com/
IPO date
Oct 04, 2012
Employees
12
Domiciled in
US
Incorporated in
US
Legal address
c/o DELAWARE CORPORATE SERVICES INC., 901 N MARKET ST STE 705
Wilmington, DE 19801
US
Headquarters
9 Fourth Ave.
Waltham, MA 02451
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT